Sotagliflozin won't die, and in the absence of a marketing partner, management is committed to pursuing FDA approval for the heart failure indication on their own. Upcoming studies of rival drugs ...
Lexicon Pharmaceuticals' launch of Inpefa continues to progress very slowly; prescriptions grew nearly 50% QoQ, but revenue is still below $2M and missing sell-side expectations. New leadership and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback